Rare Disease Trial Updates: March 2026
In March 2026, Trial Friend tracked 4 rare disease clinical trial updates across 4 conditions, including 4 FDA-related actions and 0 trial status changes, alongside enrollment updates and new trial site openings sourced from ClinicalTrials.gov and FDA announcements.
This is a permanent monthly archive. For the latest updates, see the live current events feed.
Major Updates: FDA Actions, Status Changes & Results
The FDA granted orphan drug designation to tamibarotene, developed by Rege Nephro Co., Ltd., on 2026-03-26 for the treatment of autosomal dominant polycystic kidney disease. Orphan designation is an incentive for rare disease drug development, not an approval: it gives the sponsor tax credits, fee waivers, and 7 years of market exclusivity if the drug is eventually approved. It often signals that a company is committing to a full development program.
The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).
The FDA granted orphan drug designation to tadalafil, developed by Shenzhen Hanhui Pharmaceutical Technology Co., Ltd, on 2026-03-23 for the treatment of idiopathic pulmonary fibrosis. Orphan designation is an incentive for rare disease drug development, not an approval: it gives the sponsor tax credits, fee waivers, and 7 years of market exclusivity if the drug is eventually approved. It often signals that a company is committing to a full development program.
The FDA granted orphan drug designation to meloxicam, developed by AniMusCure Inc., on 2026-03-02 for the treatment of amyotrophic lateral sclerosis. Orphan designation is an incentive for rare disease drug development, not an approval: it gives the sponsor tax credits, fee waivers, and 7 years of market exclusivity if the drug is eventually approved. It often signals that a company is committing to a full development program.